{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:31Z","timestamp":1792787371693,"version":"4.5.0"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8230010226"],"award-info":[{"award-number":["8230010226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) has identified at least three major subtypes of DLBCL, each of which has distinct clinical, biological, and genetic features: activated B-cell (ABC)-like DLBCL, germinal-center B-cell (GCB)-like DLBCL, and unclassified. Different origins are associated with different responses to chemotherapy and targeted agents. Despite DLBCL being a highly heterogeneous disease, more than 60% of patients with DLBCL can be cured after using rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to inhibit the growth of cancer cells while targeting the CD20 receptor. In recent decades, the improvement of diagnostic levels has led to a refinement classification of DLBCL and the development of new therapeutic approaches. The objective of this review was to summarize the latest studies examining genetic lesions and therapies for DLBCL.<\/jats:p>","DOI":"10.1007\/s00277-024-05880-z","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:01:52Z","timestamp":1721174512000},"page":"3315-3334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Advances in biology, diagnosis and treatment of DLBCL"],"prefix":"10.1007","volume":"103","author":[{"given":"Yuanfei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-5581","authenticated-orcid":false,"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"6","key":"5880_CR1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/annonc\/mdv019","volume":"26","author":"M Testoni","year":"2015","unstructured":"Testoni M et al (2015) Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol 26(6):1069\u20131080","journal-title":"Ann Oncol"},{"issue":"1","key":"5880_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH (2014) Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11(1):12\u201323","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"5880_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"key":"5880_CR4","doi-asserted-by":"crossref","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7): 1720\u20131748","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"8","key":"5880_CR5","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","volume":"101","author":"JA Martinez-Climent","year":"2003","unstructured":"Martinez-Climent JA et al (2003) Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101(8):3109\u20133117","journal-title":"Blood"},{"issue":"3","key":"5880_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","volume":"130","author":"R Kridel","year":"2017","unstructured":"Kridel R et al (2017) Predicting transformation of follicular lymphoma. Blood 130(3):258\u2013266","journal-title":"Blood"},{"issue":"11","key":"5880_CR7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","volume":"123","author":"A Bouska","year":"2014","unstructured":"Bouska A et al (2014) Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 123(11):1681\u20131690","journal-title":"Blood"},{"issue":"1","key":"5880_CR8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L et al (2014) Genetics of follicular lymphoma transformation. Cell Rep 6(1):130\u2013140","journal-title":"Cell Rep"},{"issue":"1","key":"5880_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.880","volume":"27","author":"D Rossi","year":"2009","unstructured":"Rossi D, Gaidano G (2009) Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 27(1):1\u201310","journal-title":"Hematol Oncol"},{"issue":"15","key":"5880_CR10","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","volume":"122","author":"E Chigrinova","year":"2013","unstructured":"Chigrinova E et al (2013) Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122(15):2673\u20132682","journal-title":"Blood"},{"issue":"3","key":"5880_CR11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00042560-200107010-00009","volume":"27","author":"MI Tiirikainen","year":"2001","unstructured":"Tiirikainen MI et al (2001) DNA copy number alterations in HIV-positive and HIV-negative patients with diffuse large-cell lymphomas. J Acquir Immune Defic Syndr 27(3):272\u2013276","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"5880_CR12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOH.0b013e328338f6b6","volume":"17","author":"A Gucalp","year":"2010","unstructured":"Gucalp A, Noy A (2010) Spectrum of HIV lymphoma 2009. Curr Opin Hematol 17(4):362\u2013367","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"5880_CR13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0959-8049(01)00119-8","volume":"37","author":"A Carbone","year":"2001","unstructured":"Carbone A et al (2001) Genetic pathways and histogenetic models of AIDS-related lymphomas. Eur J Cancer 37(10):1270\u20131275","journal-title":"Eur J Cancer"},{"issue":"11","key":"5880_CR14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/17512433.2019.1683447","volume":"12","author":"F Frontzek","year":"2019","unstructured":"Frontzek F, Lenz G (2019) Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev Clin Pharmacol 12(11):1059\u20131067","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"5880_CR15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690","journal-title":"Nat Med"},{"issue":"15","key":"5880_CR16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R et al (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378(15):1396\u20131407","journal-title":"N Engl J Med"},{"issue":"4","key":"5880_CR17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW et al (2020) A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37(4):551-568 e14","journal-title":"Cancer Cell"},{"issue":"13","key":"5880_CR18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/bloodadvances.2019000251","volume":"3","author":"A Barraclough","year":"2019","unstructured":"Barraclough A et al (2019) COO and MYC\/BCL2 status do not predict outcome among patients with stage I\/II DLBCL: a retrospective multicenter study. Blood Adv 3(13):2013\u20132021","journal-title":"Blood Adv"},{"issue":"5","key":"5880_CR19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bjh.13766","volume":"171","author":"A Kumar","year":"2015","unstructured":"Kumar A et al (2015) Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 171(5):776\u2013783","journal-title":"Br J Haematol"},{"issue":"9880","key":"5880_CR20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826","journal-title":"Lancet"},{"issue":"26","key":"5880_CR21","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW et al (2015) Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 33(26):2848\u20132856","journal-title":"J Clin Oncol"},{"issue":"6","key":"5880_CR22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/10428194.2020.1869965","volume":"62","author":"A Augustyn","year":"2021","unstructured":"Augustyn A et al (2021) The impact of cell-of-origin, MYC\/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1361\u20131369","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5880_CR23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","volume":"114","author":"NA Johnson","year":"2009","unstructured":"Johnson NA et al (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114(11):2273\u20132279","journal-title":"Blood"},{"issue":"18","key":"5880_CR24","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","volume":"131","author":"DW Scott","year":"2018","unstructured":"Scott DW et al (2018) High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131(18):2060\u20132064","journal-title":"Blood"},{"issue":"22","key":"5880_CR25","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313\u20132323","journal-title":"N Engl J Med"},{"issue":"6769","key":"5880_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511","journal-title":"Nature"},{"issue":"17","key":"5880_CR27","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","volume":"100","author":"G Wright","year":"2003","unstructured":"Wright G et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100(17):9991\u20139996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"5880_CR28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","volume":"198","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851\u2013862","journal-title":"J Exp Med"},{"issue":"15","key":"5880_CR29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362(15):1417\u20131429","journal-title":"N Engl J Med"},{"issue":"25","key":"5880_CR30","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937\u20131947","journal-title":"N Engl J Med"},{"issue":"9","key":"5880_CR31","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"C Visco","year":"2012","unstructured":"Visco C et al (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103\u20132113","journal-title":"Leukemia"},{"issue":"2","key":"5880_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbcan.2018.01.001","volume":"1869","author":"L Guo","year":"2018","unstructured":"Guo L et al (2018) Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. Biochim Biophys Acta Rev Cancer 1869(2):85\u201396","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"5880_CR33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","volume":"97","author":"WH Wilson","year":"2012","unstructured":"Wilson WH et al (2012) A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5):758\u2013765","journal-title":"Haematologica"},{"issue":"5","key":"5880_CR34","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S Monti","year":"2005","unstructured":"Monti S et al (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105(5):1851\u20131861","journal-title":"Blood"},{"issue":"7463","key":"5880_CR35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415\u2013421","journal-title":"Nature"},{"issue":"7457","key":"5880_CR36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214\u2013218","journal-title":"Nature"},{"issue":"7","key":"5880_CR37","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","volume":"122","author":"RD Morin","year":"2013","unstructured":"Morin RD et al (2013) Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122(7):1256\u20131265","journal-title":"Blood"},{"issue":"9","key":"5880_CR38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L et al (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43(9):830\u2013837","journal-title":"Nat Genet"},{"issue":"7360","key":"5880_CR39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD et al (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298\u2013303","journal-title":"Nature"},{"issue":"27","key":"5880_CR40","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.0903854106","volume":"106","author":"M Saito","year":"2009","unstructured":"Saito M et al (2009) BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci USA 106(27):11294\u201311299","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6844","key":"5880_CR41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","volume":"412","author":"L Pasqualucci","year":"2001","unstructured":"Pasqualucci L et al (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412(6844):341\u2013346","journal-title":"Nature"},{"issue":"5","key":"5880_CR42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccr.2005.03.037","volume":"7","author":"G Cattoretti","year":"2005","unstructured":"Cattoretti G et al (2005) Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7(5):445\u2013455","journal-title":"Cancer Cell"},{"issue":"11","key":"5880_CR43","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.leu.2404856","volume":"21","author":"J Iqbal","year":"2007","unstructured":"Iqbal J et al (2007) Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21(11):2332\u20132343","journal-title":"Leukemia"},{"issue":"3","key":"5880_CR44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","volume":"12","author":"M Saito","year":"2007","unstructured":"Saito M et al (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12(3):280\u2013292","journal-title":"Cancer Cell"},{"issue":"26","key":"5880_CR45","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1182\/blood-2009-02-204362","volume":"114","author":"P Juszczynski","year":"2009","unstructured":"Juszczynski P et al (2009) BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase. PTPROt Blood 114(26):5315\u20135321","journal-title":"PTPROt Blood"},{"issue":"13","key":"5880_CR46","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1084\/jem.20121387","volume":"209","author":"K Basso","year":"2012","unstructured":"Basso K et al (2012) BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 209(13):2455\u20132465","journal-title":"J Exp Med"},{"issue":"7","key":"5880_CR47","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2006-05-022517","volume":"108","author":"YW Chen","year":"2006","unstructured":"Chen YW et al (2006) High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood 108(7):2373\u20132383","journal-title":"Blood"},{"issue":"23","key":"5880_CR48","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","volume":"116","author":"G Ott","year":"2010","unstructured":"Ott G et al (2010) Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116(23):4916\u20134925","journal-title":"Blood"},{"issue":"12","key":"5880_CR49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253\u20132263","journal-title":"Blood"},{"issue":"11","key":"5880_CR50","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","volume":"107","author":"JN Winter","year":"2006","unstructured":"Winter JN et al (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11):4207\u20134213","journal-title":"Blood"},{"issue":"7","key":"5880_CR51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190802108888","volume":"49","author":"Y Oki","year":"2008","unstructured":"Oki Y et al (2008) Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49(7):1345\u20131351","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"5880_CR52","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","volume":"118","author":"N Akyurek","year":"2012","unstructured":"Akyurek N et al (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118(17):4173\u20134183","journal-title":"Cancer"},{"issue":"33","key":"5880_CR53","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2009.22.7058","volume":"27","author":"C Copie-Bergman","year":"2009","unstructured":"Copie-Bergman C et al (2009) Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 27(33):5573\u20135579","journal-title":"J Clin Oncol"},{"issue":"6","key":"5880_CR54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","volume":"18","author":"J Mandelbaum","year":"2010","unstructured":"Mandelbaum J et al (2010) BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18(6):568\u2013579","journal-title":"Cancer Cell"},{"issue":"7247","key":"5880_CR55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717\u2013721","journal-title":"Nature"},{"issue":"7247","key":"5880_CR56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature07969","volume":"459","author":"M Kato","year":"2009","unstructured":"Kato M et al (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature 459(7247):712\u2013716","journal-title":"Nature"},{"issue":"6","key":"5880_CR57","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","volume":"18","author":"DP Calado","year":"2010","unstructured":"Calado DP et al (2010) Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18(6):580\u2013589","journal-title":"Cancer Cell"},{"issue":"36","key":"5880_CR58","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G et al (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105(36):13520\u201313525","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"5880_CR59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","volume":"204","author":"G Lenz","year":"2007","unstructured":"Lenz G et al (2007) Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204(3):633\u2013643","journal-title":"J Exp Med"},{"issue":"1","key":"5880_CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-7613(02)00335-7","volume":"17","author":"AL Shaffer","year":"2002","unstructured":"Shaffer AL et al (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17(1):51\u201362","journal-title":"Immunity"},{"issue":"10","key":"5880_CR61","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG et al (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 109(10):3879\u20133884","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5870","key":"5880_CR62","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676\u20131679","journal-title":"Science"},{"issue":"7277","key":"5880_CR63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392","journal-title":"Nature"},{"issue":"7332","key":"5880_CR64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115\u2013119","journal-title":"Nature"},{"issue":"5595","key":"5880_CR65","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595):1039\u20131043","journal-title":"Science"},{"issue":"13","key":"5880_CR66","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2013-01-475772","volume":"122","author":"P Bonetti","year":"2013","unstructured":"Bonetti P et al (2013) Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood 122(13):2233\u20132241","journal-title":"Blood"},{"issue":"9","key":"5880_CR67","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/0008-5472.CAN-10-2380","volume":"71","author":"A Scuto","year":"2011","unstructured":"Scuto A et al (2011) STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 71(9):3182\u20133188","journal-title":"Cancer Res"},{"issue":"3","key":"5880_CR68","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","volume":"111","author":"BB Ding","year":"2008","unstructured":"Ding BB et al (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3):1515\u20131523","journal-title":"Blood"},{"issue":"13","key":"5880_CR69","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2013-06-508028","volume":"122","author":"H Nogai","year":"2013","unstructured":"Nogai H et al (2013) IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood 122(13):2242\u20132250","journal-title":"Blood"},{"issue":"1","key":"5880_CR70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","volume":"165","author":"J Iqbal","year":"2004","unstructured":"Iqbal J et al (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165(1):159\u2013166","journal-title":"Am J Pathol"},{"issue":"24","key":"5880_CR71","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-11-0267","volume":"17","author":"J Iqbal","year":"2011","unstructured":"Iqbal J et al (2011) BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 17(24):7785\u20137795","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5880_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","volume":"98","author":"C Visco","year":"2013","unstructured":"Visco C et al (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98(2):255\u2013263","journal-title":"Haematologica"},{"issue":"8","key":"5880_CR73","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","volume":"119","author":"W Klapper","year":"2012","unstructured":"Klapper W et al (2012) Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 119(8):1882\u20131887","journal-title":"Blood"},{"issue":"10","key":"5880_CR74","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.humpath.2014.06.005","volume":"45","author":"SL Kendrick","year":"2014","unstructured":"Kendrick SL et al (2014) BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 45(10):2144\u20132153","journal-title":"Hum Pathol"},{"issue":"6","key":"5880_CR75","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","volume":"26","author":"JM Schuetz","year":"2012","unstructured":"Schuetz JM et al (2012) BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26(6):1383\u20131390","journal-title":"Leukemia"},{"issue":"2","key":"5880_CR76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.2008.057257","volume":"62","author":"D de Jong","year":"2009","unstructured":"de Jong D et al (2009) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 62(2):128\u2013138","journal-title":"J Clin Pathol"},{"issue":"7","key":"5880_CR77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","volume":"25","author":"D de Jong","year":"2007","unstructured":"de Jong D et al (2007) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2013a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25(7):805\u2013812","journal-title":"J Clin Oncol"},{"issue":"6","key":"5880_CR78","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","volume":"24","author":"J Iqbal","year":"2006","unstructured":"Iqbal J et al (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24(6):961\u2013968","journal-title":"J Clin Oncol"},{"issue":"7337","key":"5880_CR79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471(7337):189\u2013195","journal-title":"Nature"},{"issue":"4","key":"5880_CR80","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J et al (2013) Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110(4):1398\u20131403","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"5880_CR81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42(2):181\u2013185","journal-title":"Nat Genet"},{"issue":"8","key":"5880_CR82","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","volume":"109","author":"MT McCabe","year":"2012","unstructured":"McCabe MT et al (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 109(8):2989\u20132994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"52","key":"5880_CR83","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","volume":"109","author":"W Qi","year":"2012","unstructured":"Qi W et al (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 109(52):21360\u201321365","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7427","key":"5880_CR84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427):108\u2013112","journal-title":"Nature"},{"issue":"11","key":"5880_CR85","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","volume":"8","author":"SK Knutson","year":"2012","unstructured":"Knutson SK et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8(11):890\u2013896","journal-title":"Nat Chem Biol"},{"issue":"1","key":"5880_CR86","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbagen.2013.09.020","volume":"1840","author":"S Kant","year":"2014","unstructured":"Kant S, Kumar A, Singh SM (2014) Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 1840(1):294\u2013302","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"5880_CR87","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2014-07-587337","volume":"125","author":"F Cayrol","year":"2015","unstructured":"Cayrol F et al (2015) Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 125(5):841\u2013851","journal-title":"Blood"},{"issue":"12","key":"5880_CR88","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdz386","volume":"30","author":"S Ciavarella","year":"2019","unstructured":"Ciavarella S et al (2019) Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 30(12):2015","journal-title":"Ann Oncol"},{"issue":"12","key":"5880_CR89","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","volume":"29","author":"S Ciavarella","year":"2018","unstructured":"Ciavarella S et al (2018) Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 29(12):2363\u20132370","journal-title":"Ann Oncol"},{"issue":"8","key":"5880_CR90","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","volume":"103","author":"M de Charette","year":"2018","unstructured":"de Charette M, Houot R (2018) Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103(8):1256\u20131268","journal-title":"Haematologica"},{"issue":"18","key":"5880_CR91","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2016-08-737239","volume":"129","author":"S Pandey","year":"2017","unstructured":"Pandey S et al (2017) IL-4\/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood 129(18):2507\u20132518","journal-title":"Blood"},{"issue":"6","key":"5880_CR92","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N et al (2021) Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11(6):1468\u20131489","journal-title":"Cancer Discov"},{"issue":"1","key":"5880_CR93","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218","journal-title":"Genome Biol"},{"issue":"3","key":"5880_CR94","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E et al (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83\u201387","journal-title":"Pathologica"},{"issue":"1","key":"5880_CR95","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"key":"5880_CR96","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2020.00351","volume":"10","author":"G Opinto","year":"2020","unstructured":"Opinto G et al (2020) The Tumor Microenvironment of DLBCL in the Computational Era. Front Oncol 10:351","journal-title":"Front Oncol"},{"issue":"4","key":"5880_CR97","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.23398","volume":"88","author":"C Keane","year":"2013","unstructured":"Keane C et al (2013) CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 88(4):273\u2013276","journal-title":"Am J Hematol"},{"issue":"1","key":"5880_CR98","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","volume":"135","author":"PN Meyer","year":"2011","unstructured":"Meyer PN et al (2011) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135(1):54\u201361","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"5880_CR99","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-010-1060-8","volume":"90","author":"N Niitsu","year":"2011","unstructured":"Niitsu N et al (2011) A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Ann Hematol 90(2):185\u2013192","journal-title":"Ann Hematol"},{"issue":"28","key":"5880_CR100","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3460\u20133467","journal-title":"J Clin Oncol"},{"issue":"28","key":"5880_CR101","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452\u20133459","journal-title":"J Clin Oncol"},{"key":"5880_CR102","doi-asserted-by":"crossref","unstructured":"Hu S et al (2013) MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20): 4021\u201331; quiz 4250","DOI":"10.1182\/blood-2012-10-460063"},{"issue":"22","key":"5880_CR103","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","volume":"35","author":"AM Staiger","year":"2017","unstructured":"Staiger AM et al (2017) Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 35(22):2515\u20132526","journal-title":"J Clin Oncol"},{"issue":"17","key":"5880_CR104","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","volume":"15","author":"WW Choi","year":"2009","unstructured":"Choi WW et al (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494\u20135502","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5880_CR105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","volume":"208","author":"JJ Muris","year":"2006","unstructured":"Muris JJ et al (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208(5):714\u2013723","journal-title":"J Pathol"},{"issue":"11","key":"5880_CR106","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","volume":"109","author":"H Nyman","year":"2007","unstructured":"Nyman H et al (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109(11):4930\u20134935","journal-title":"Blood"},{"issue":"3","key":"5880_CR107","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","volume":"26","author":"Y Natkunam","year":"2008","unstructured":"Natkunam Y et al (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26(3):447\u2013454","journal-title":"J Clin Oncol"},{"issue":"2","key":"5880_CR108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","volume":"29","author":"PN Meyer","year":"2011","unstructured":"Meyer PN et al (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200\u2013207","journal-title":"J Clin Oncol"},{"issue":"6","key":"5880_CR109","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","volume":"139","author":"EA Hawkes","year":"2022","unstructured":"Hawkes EA, Barraclough A, Sehn LH (2022) Limited-stage diffuse large B-cell lymphoma. Blood 139(6):822\u2013834","journal-title":"Blood"},{"issue":"1","key":"5880_CR110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","volume":"174","author":"S Chaganti","year":"2016","unstructured":"Chaganti S et al (2016) Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 174(1):43\u201356","journal-title":"Br J Haematol"},{"issue":"23","key":"5880_CR111","first-page":"2262","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse Large B-Cell Lymphoma. Reply N Engl J Med 384(23):2262","journal-title":"Reply N Engl J Med"},{"issue":"17","key":"5880_CR112","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2021012052","volume":"138","author":"G Chiodin","year":"2021","unstructured":"Chiodin G et al (2021) Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood 138(17):1570\u20131582","journal-title":"Blood"},{"issue":"3","key":"5880_CR113","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1158\/1078-0432.CCR-20-1632","volume":"27","author":"A Rovida","year":"2021","unstructured":"Rovida A et al (2021) Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. Clin Cancer Res 27(3):729\u2013739","journal-title":"Clin Cancer Res"},{"key":"5880_CR114","doi-asserted-by":"crossref","unstructured":"Wang L et al (2022) Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study. Br J Dermatol","DOI":"10.1111\/bjd.21791"},{"issue":"5","key":"5880_CR115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000001852","volume":"46","author":"M Koo","year":"2022","unstructured":"Koo M et al (2022) Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. Am J Surg Pathol 46(5):643\u2013654","journal-title":"Am J Surg Pathol"},{"key":"5880_CR116","doi-asserted-by":"crossref","unstructured":"Loeffler-Wirth H et al (2022) Classifying germinal center derived lymphomas\u2014Navigate a complex transcriptional landscape. Cancers (Basel) 14(14)","DOI":"10.3390\/cancers14143434"},{"key":"5880_CR117","doi-asserted-by":"crossref","unstructured":"Pindzola GM et al (2022) Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. Blood","DOI":"10.1182\/blood.2022015926"},{"issue":"1","key":"5880_CR118","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/s41467-022-30053-9","volume":"13","author":"S Amanda","year":"2022","unstructured":"Amanda S et al (2022) IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma. Nat Commun 13(1):2420","journal-title":"Nat Commun"},{"issue":"7","key":"5880_CR119","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/bloodadvances.2021006034","volume":"6","author":"L Frauenfeld","year":"2022","unstructured":"Frauenfeld L et al (2022) Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Adv 6(7):2361\u20132372","journal-title":"Blood Adv"},{"issue":"1","key":"5880_CR120","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1038\/s41598-020-69884-1","volume":"10","author":"E Ricker","year":"2020","unstructured":"Ricker E et al (2020) Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Sci Rep 10(1):13094","journal-title":"Sci Rep"},{"issue":"7","key":"5880_CR121","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","volume":"29","author":"H Horn","year":"2015","unstructured":"Horn H et al (2015) Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 29(7):1564\u20131570","journal-title":"Leukemia"},{"issue":"3","key":"5880_CR122","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41379-021-00909-4","volume":"35","author":"M Khanlari","year":"2022","unstructured":"Khanlari M et al (2022) Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. Mod Pathol 35(3):419\u2013426","journal-title":"Mod Pathol"},{"issue":"3","key":"5880_CR123","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000001785","volume":"46","author":"H Fang","year":"2022","unstructured":"Fang H et al (2022) Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas. Am J Surg Pathol 46(3):326\u2013335","journal-title":"Am J Surg Pathol"},{"key":"5880_CR124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergen.2017.11.007","volume":"220","author":"D Minakata","year":"2018","unstructured":"Minakata D et al (2018) A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. Cancer Genet 220:44\u201348","journal-title":"Cancer Genet"},{"issue":"7","key":"5880_CR125","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ng.2666","volume":"45","author":"DE Tan","year":"2013","unstructured":"Tan DE et al (2013) Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet 45(7):804\u2013807","journal-title":"Nat Genet"},{"issue":"3","key":"5880_CR126","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/imm.13388","volume":"164","author":"M Strazza","year":"2021","unstructured":"Strazza M et al (2021) PD-1-induced proliferating T cells exhibit a distinct transcriptional signature. Immunology 164(3):555\u2013568","journal-title":"Immunology"},{"issue":"4","key":"5880_CR127","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12032-021-01470-5","volume":"38","author":"J Li","year":"2021","unstructured":"Li J et al (2021) Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma. Med Oncol 38(4):33","journal-title":"Med Oncol"},{"issue":"7","key":"5880_CR128","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.cell.2021.02.027","volume":"184","author":"P Gonzalez-Figueroa","year":"2021","unstructured":"Gonzalez-Figueroa P et al (2021) Follicular regulatory T cells produce neuritin to regulate B cells. Cell 184(7):1775-1789 e19","journal-title":"Cell"},{"issue":"6","key":"5880_CR129","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.2019002654","volume":"136","author":"T Jo","year":"2020","unstructured":"Jo T et al (2020) LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood 136(6):684\u2013697","journal-title":"Blood"},{"issue":"2","key":"5880_CR130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood.2019001866","volume":"135","author":"P Bucher","year":"2020","unstructured":"Bucher P et al (2020) Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood 135(2):121\u2013132","journal-title":"Blood"},{"issue":"4","key":"5880_CR131","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2016.03.006","volume":"29","author":"Y Yang","year":"2016","unstructured":"Yang Y et al (2016) Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma. Cancer Cell 29(4):494\u2013507","journal-title":"Cancer Cell"},{"issue":"2","key":"5880_CR132","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.2020007683","volume":"138","author":"G Duns","year":"2021","unstructured":"Duns G et al (2021) Characterization of DLBCL with a PMBL gene expression signature. Blood 138(2):136\u2013148","journal-title":"Blood"},{"key":"5880_CR133","doi-asserted-by":"crossref","unstructured":"Watanabe T (2021) The tumor microenvironment in follicular lymphoma: its pro-malignancy role with therapeutic potential. Int J Mol Sci 22(10)","DOI":"10.3390\/ijms22105352"},{"issue":"27","key":"5880_CR134","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"4","key":"5880_CR135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/joim.12813","volume":"284","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC et al (2018) FDG-PET\/CT in the management of lymphomas: current status and future directions. J Intern Med 284(4):358\u2013376","journal-title":"J Intern Med"},{"issue":"3","key":"5880_CR136","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00259-013-2623-4","volume":"41","author":"HJ Adams","year":"2014","unstructured":"Adams HJ et al (2014) FDG PET\/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 41(3):565\u2013574","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"26","key":"5880_CR137","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO et al (2020) Positron emission tomography\u2013directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol 38(26):3003\u20133011","journal-title":"J Clin Oncol"},{"issue":"2","key":"5880_CR138","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T et al (2018) R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131(2):174\u2013181","journal-title":"Blood"},{"issue":"14","key":"5880_CR139","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","volume":"26","author":"DO Persky","year":"2008","unstructured":"Persky DO et al (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26(14):2258\u20132263","journal-title":"J Clin Oncol"},{"issue":"3","key":"5880_CR140","first-page":"345","volume":"14","author":"M Roschewski","year":"2024","unstructured":"Roschewski M, Phelan JD, Jaffe ES (2024) Primary large b-cell lymphomas of immune-privileged sites. Blood 14(3):345\u2013357","journal-title":"Blood"},{"issue":"11","key":"5880_CR141","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013\u20131022","journal-title":"Lancet Oncol"},{"issue":"9","key":"5880_CR142","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4161\/cbt.29504","volume":"15","author":"S Shahbazi","year":"2014","unstructured":"Shahbazi S, Peer CJ, Figg WD (2014) Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. Cancer Biol Ther 15(9):1117\u20131119","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"5880_CR143","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","volume":"56","author":"OO Odejide","year":"2015","unstructured":"Odejide OO et al (2015) Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma 56(3):716\u2013724","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5880_CR144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2014.12.042","volume":"92","author":"J Kwon","year":"2015","unstructured":"Kwon J et al (2015) Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 92(1):91\u201398","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"30","key":"5880_CR145","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH et al (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(30):4952\u20134957","journal-title":"J Clin Oncol"},{"issue":"3","key":"5880_CR146","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS et al (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 33(3):251\u2013257","journal-title":"J Clin Oncol"},{"issue":"7","key":"5880_CR147","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","volume":"15","author":"U Vitolo","year":"2014","unstructured":"Vitolo U et al (2014) Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 15(7):730\u2013737","journal-title":"Lancet Oncol"},{"issue":"12","key":"5880_CR148","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS et al (2021) Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol 39(12):1329\u20131338","journal-title":"J Clin Oncol"},{"issue":"12","key":"5880_CR149","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS et al (2021) ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 39(12):1317\u20131328","journal-title":"J Clin Oncol"},{"issue":"31","key":"5880_CR150","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP et al (2017) Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 35(31):3538\u20133546","journal-title":"J Clin Oncol"},{"issue":"8","key":"5880_CR151","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922\u2013926","journal-title":"Nat Med"},{"issue":"10","key":"5880_CR152","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","volume":"19","author":"RL Elstrom","year":"2008","unstructured":"Elstrom RL et al (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10):1770\u20131773","journal-title":"Ann Oncol"},{"issue":"2","key":"5880_CR153","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2013.338","volume":"109","author":"CY Cheah","year":"2013","unstructured":"Cheah CY et al (2013) Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109(2):312\u2013317","journal-title":"Br J Cancer"},{"issue":"1","key":"5880_CR154","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.clml.2017.10.003","volume":"18","author":"MC Cheung","year":"2018","unstructured":"Cheung MC et al (2018) Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission. Clin Lymphoma Myeloma Leuk 18(1):e27\u2013e34","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5880_CR155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e31826c5907","volume":"18","author":"LH Sehn","year":"2012","unstructured":"Sehn LH (2012) Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J 18(5):421\u2013426","journal-title":"Cancer J"},{"issue":"5","key":"5880_CR156","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.ijrobp.2010.02.015","volume":"78","author":"S Devic","year":"2010","unstructured":"Devic S et al (2010) Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography\/computed tomography: still a Pandora\u2019s box? Int J Radiat Oncol Biol Phys 78(5):1555\u20131562","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"5880_CR157","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andre","year":"2017","unstructured":"Andre MPE et al (2017) Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35(16):1786\u20131794","journal-title":"J Clin Oncol"},{"issue":"7","key":"5880_CR158","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG et al (2016) Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 43(7):1209\u20131219","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5880_CR159","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12149-020-01531-1","volume":"35","author":"P Zhao","year":"2021","unstructured":"Zhao P, Yu T, Pan Z (2021) Prognostic value of the baseline 18F-FDG PET\/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med 35(1):24\u201330","journal-title":"Ann Nucl Med"},{"issue":"12","key":"5880_CR160","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH et al (2021) Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(12):1643-1653 e3","journal-title":"Cancer Cell"},{"issue":"27","key":"5880_CR161","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"issue":"23","key":"5880_CR162","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/jcm12237376","volume":"12","author":"E Gonzalez Barca","year":"2023","unstructured":"Gonzalez Barca E (2023) Developing new strategies for relapsed\/refractory diffuse large B-Cell lymphoma. J Clin Med 12(23):173\u2013187","journal-title":"J Clin Med"},{"issue":"16","key":"5880_CR163","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"key":"5880_CR164","doi-asserted-by":"crossref","first-page":"204062071984158","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA (2019) CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol 10:2040620719841581","journal-title":"Ther Adv Hematol"},{"issue":"19","key":"5880_CR165","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D et al (2020) Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 4(19):4669\u20134678","journal-title":"Blood Adv"},{"issue":"10","key":"5880_CR166","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN et al (2017) Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 25(10):2245\u20132253","journal-title":"Mol Ther"},{"issue":"10402","key":"5880_CR167","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T et al (2023) Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet 402(10402):641\u2013654","journal-title":"Lancet"},{"issue":"10254","key":"5880_CR168","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"1","key":"5880_CR169","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"26","key":"5880_CR170","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"18","key":"5880_CR171","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH (2022) CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood 139(18):2737\u20132746","journal-title":"Blood"},{"issue":"3","key":"5880_CR172","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A et al (2022) A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol 198(3):492\u2013502","journal-title":"Br J Haematol"},{"issue":"3","key":"5880_CR173","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjh.19201","volume":"204","author":"AL Al-Mashhadi","year":"2024","unstructured":"Al-Mashhadi AL et al (2024) Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed\/refractory large B-cell lymphomas. Br J Haematol 204(3):839\u2013848","journal-title":"Br J Haematol"},{"issue":"1","key":"5880_CR174","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"24","key":"5880_CR175","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK et al (2019) Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol 37(24):2105\u20132119","journal-title":"J Clin Oncol"},{"issue":"15","key":"5880_CR176","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS et al (2017) A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 23(15):4127\u20134137","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5880_CR177","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833","journal-title":"J Clin Oncol"},{"issue":"6","key":"5880_CR178","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","volume":"23","author":"MG Zauderer","year":"2022","unstructured":"Zauderer MG et al (2022) EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol 23(6):758\u2013767","journal-title":"Lancet Oncol"},{"issue":"3","key":"5880_CR179","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pathol.2020.12.003","volume":"53","author":"F Harrington","year":"2021","unstructured":"Harrington F et al (2021) Genomic characterisation of diffuse large B-cell lymphoma. Pathology 53(3):367\u2013376","journal-title":"Pathology"},{"issue":"4","key":"5880_CR180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"10","key":"5880_CR181","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A (2021) Loncastuximab tesirine: first approval. Drugs 81(10):1229\u20131233","journal-title":"Drugs"},{"issue":"6","key":"5880_CR182","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790\u2013800","journal-title":"Lancet Oncol"},{"issue":"7","key":"5880_CR183","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N et al (2020) Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7(7):e511\u2013e522","journal-title":"Lancet Haematol"},{"issue":"22","key":"5880_CR184","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","volume":"27","author":"PL Zinzani","year":"2021","unstructured":"Zinzani PL et al (2021) RE-MIND: comparing tafasitamab+ lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 27(22):6124\u20136134","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5880_CR185","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640\u2013654","journal-title":"N Engl J Med"},{"issue":"8","key":"5880_CR186","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"18","key":"5880_CR187","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959\u20131970","journal-title":"J Clin Oncol"},{"issue":"10306","key":"5880_CR188","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M et al (2021) Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet 398(10306):1157\u20131169","journal-title":"Lancet"},{"issue":"8","key":"5880_CR189","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"26","key":"5880_CR190","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"issue":"3","key":"5880_CR191","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153\u2013167","journal-title":"Nat Rev Immunol"},{"key":"5880_CR192","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X et al (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J 17:661\u2013674","journal-title":"Comput Struct Biotechnol J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05880-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05880-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:16:51Z","timestamp":1724822211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05880-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":192,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5880"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05880-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was reviewed and approved by Department of\u00a0Hematology, The First Affiliated Hospital, College of Medicine,\u00a0Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}